NCT04433260

Brief Summary

The current COVID-19 pandemic has affected more than 3 million people worldwide across more than 200 countries. In the United Kingdom alone, at the end of April, there were almost 160,000 confirmed cases with more than 20,000 deaths. This has undoubtedly had significant physical and economical impact on the public. Healthcare workers are at high risk of developing life-threatening infectious diseases with increased exposure to patients' blood and bodily fluids. As such, health care workers arguably experience heightened anxiety and are predisposed to greater negative psycho-social impact from the current COVID-19 pandemic. The aim of this study is to evaluate the physical and psychological impact of COVID-19 on healthcare workers. This will be performed in two phases. In phase 1, investigators will collect information to evaluate the current psychiatric symptom profile (in particular, screening for anxiety or depression related symptoms), alcohol use, sleep-related complaints and overall well-being among healthcare workers who participate in this survey (with a focus on junior doctors). In addition the association of these mental health and behavioural parameters with the prevalence of stressful occasions, such as long-hours, unpredictability of work / redeployment, availability of personal protection equipment and concerns regarding family/relationship and self will be assessed. In phase 2, investigators will then reassess for the development or progression of psychiatric symptoms, use of alcohol and other substances, behavioural or interpersonal relationship changes as well as physical well-being at 6 weeks and 4- months. Physical well-being is assessed through the presence of suspected or confirmed COVID-19 infection and absence from work. Specifically, investigators will study the impact of variable provision of personal protection equipment (supply and training), extended working hours, and concern for well-being of family members, on work morale and anxiety levels. Another aim is also study the longer term mental health consequences of the current pandemic on health care workers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,721

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 9, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 16, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

July 25, 2020

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2021

Completed
3.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 16, 2024

Completed
Last Updated

February 13, 2025

Status Verified

February 1, 2025

Enrollment Period

8 months

First QC Date

June 9, 2020

Last Update Submit

February 11, 2025

Conditions

Keywords

healthcare professionalsPersonal protective equipmentcovid-19SARS-CoV2

Outcome Measures

Primary Outcomes (5)

  • Presence of anxiety at baseline

    Symptoms of anxiety will be investigated using the 7-item Generalised Anxiety Disorder (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety.

    baseline

  • Presence of depression at baseline

    Symptoms of depression will be investigated using the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression

    baseline

  • Proportion of those who report a combined outcome of presence of anxiety or depression at the baseline as determined by screening questionnaires used.

    Anxiety will be investigated by 7-item Generalised Anxiety Disorder and depression will be investigated by 9-item patient health questionnaire. Presence of either one of those or both will be taken as the combined outcome. For anxiety, 7-item Generalized anxiety disorder score (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. For depression, the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression Higher score corresponding to more severe degree of anxiety.

    baseline

  • Change in proportion of who report a combined outcome of either presence of anxiety or depression from baseline to the end of study

    Anxiety will be investigated by 7-item Generalised Anxiety Disorder and depression will be investigated by 9-item patient health questionnaire. Presence of either one of those or both will be taken as the combined outcome. For anxiety, 7-item Generalized anxiety disorder score (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. For depression, the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression

    4 months

  • Change in the proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of COVID-19 from baseline to the end of study

    Self reported, assessed based on the questions regarding the presence of symptoms with presence of either self reported positive test, or self-isolation of 7 or more days.

    4 months

Secondary Outcomes (12)

  • Change in prevalence of anxiety from baseline

    4 months

  • Change in prevalence of depression from baseline

    4 months followup

  • Prevalence of sleep-related issues at baseline

    At baseline

  • Change in prevalence of sleep-related issues from baseline

    4-month follow-up

  • Prevalence of a combined outcome of presence of anyone of anxiety, depression or sleep related issues at baseline.

    baseline

  • +7 more secondary outcomes

Study Arms (5)

Cases

Doctors, nurses and other healthcares ≥ 18 years of age in direct contact with patients potentially infected with COVID-19

Other: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity indexOther: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.Other: Informed consent

Internal Control

Healthcare /NHS Administrative staff who are working in the hospital, but not directly in contact with patients potentially infected with COVID-19.

Other: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity indexOther: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.Other: Informed consent

Population Control

Non-healthcare/non-NHS academic staff who are not working in the environment where patient exposure is expected.

Other: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity indexOther: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.Other: Informed consent

Follow-up cases

Doctors, nurses and other healthcare workers ≥ 18 years of age in direct contact with patients potentially infected with COVID-19 consenting to receive follow-up surveys (n \~ 400)

Other: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity indexOther: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.Other: Informed consent

Follow-up controls

Healthcare Administrative staff who are working in the hospital, not at risk of work-related exposure to patients potentially infected with COVID-19 (n\~80)

Other: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity indexOther: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.Other: Informed consent

Interventions

The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months

Also known as: Questionnaire, Questionnaire to evaluate their current quantity and frequency of alcohol use, smoking habit and mental wellbeing score (abbreviated Warwick-Edinburgh).
CasesFollow-up casesFollow-up controlsInternal ControlPopulation Control

Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.

CasesFollow-up casesFollow-up controlsInternal ControlPopulation Control

Participants will need to give their consent to participate to the survey after reading PIS

CasesFollow-up casesFollow-up controlsInternal ControlPopulation Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Doctors, nurses and other healthcares ≥ 18 years of age in direct contact with patients potentially infected with COVID-19 (n = minimum 800) Healthcare /NHS Administrative staff who are working in the hospital, but not directly in contact with patients potentially infected with COVID-19 (minimum n= 125) (internal control) Non-healthcare/non-NHS academic staff who are not working in the environment where patient exposure is expected (minimum n=125) (population control)

You may qualify if:

  • Aged \>=18
  • Electronic consent
  • Either:
  • a - healthcare workers in contact with patients with confirmed or suspected COVID-19 b - Healthcare staff not having direct patient contact c - Non-healthcare academic staff with no direct patient contact

You may not qualify if:

  • Age\<18
  • Those who are not able to understand written English will be excluded, indeed by the design and methodology of the study, as the study invite and all other information provided is in English.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ajay K Gupta

London, EC1M 6BQ, United Kingdom

Location

Related Publications (4)

  • Collett G, Kotecha A, Gupta A. Burnout and Depression Among UK-Based Healthcare Professionals: Insights From a 3-Year Prospective Cohort Study Regarding Potential Mitigation Strategies. J Occup Environ Med. 2025 Jul 1;67(7):477-482. doi: 10.1097/JOM.0000000000003364. Epub 2025 Feb 21.

  • Siddiqui I, Gupta J, Collett G, McIntosh I, Komodromos C, Godec T, Ng S, Maniero C, Antoniou S, Khan R, Kapil V, Khanji MY, Gupta AK; CoPE-HCP clinical investigators. Perceived workplace support and mental health, well-being and burnout among health care professionals during the COVID-19 pandemic: a cohort analysis. CMAJ Open. 2023 Feb 28;11(1):E191-E200. doi: 10.9778/cmajo.20220191. Print 2023 Jan-Feb.

  • Khanji MY, Collett G, Godec T, Maniero C, Ng SM, Siddiqui I, Gupta J, Kapil V, Gupta A. Improved lifestyle is associated with improved depression, anxiety and well-being over time in UK healthcare professionals during the COVID-19 pandemic: insights from the CoPE-HCP cohort study. Gen Psychiatr. 2023 Jan 20;36(1):e100908. doi: 10.1136/gpsych-2022-100908. eCollection 2023.

  • Khanji MY, Maniero C, Ng S, Siddiqui I, Gupta J, Crosby L, Antoniou S, Khan R, Kapil V, Gupta A. Early and Mid-Term Implications of the COVID-19 Pandemic on the Physical, Behavioral and Mental Health of Healthcare Professionals: The CoPE-HCP Study Protocol. Front Psychol. 2021 Feb 2;12:616280. doi: 10.3389/fpsyg.2021.616280. eCollection 2021.

MeSH Terms

Conditions

Psychological Well-BeingCOVID-19

Interventions

Patient Health QuestionnaireSurveys and QuestionnairesEthanolLeadInformed Consent

Condition Hierarchy (Ancestors)

Personal SatisfactionBehaviorPneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesPsychological TestsBehavioral Disciplines and ActivitiesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public HealthAlcoholsOrganic ChemicalsMetals, HeavyElementsInorganic ChemicalsMetalsPatient RightsHuman RightsSocial Control, FormalHealth Care Economics and OrganizationsJurisprudence

Study Officials

  • Ajay Gupta, MD, PhD

    Queen Mary University London

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 9, 2020

First Posted

June 16, 2020

Study Start

July 25, 2020

Primary Completion

March 31, 2021

Study Completion

June 16, 2024

Last Updated

February 13, 2025

Record last verified: 2025-02

Locations